FAQ

Show all

Where is Protalix BioTherapeutics headquartered?: We are headquartered in Carmiel, Israel.
When was Protalix Ltd. incorporated?: Protalix Ltd. was established in 1993.
What is Protalix BioTherapeutics' address?: Our headquarters are located at 2 Snunit Street, Science Park, P.O. Box 455, Carmiel 2161401, Israel and we can be contacted at Tel: +972-4-988-9488; Fax: 972-4-988-9489. We also maintain an office at 2 University Plaza, Suite 100, Hackensack, NJ 07601; Tel. +1-201-696-9345.
How many employees does Protalix BioTherapeutics have?: As of December 31, 2022, we had 197 employees, of whom 17 have an M.D. or a Ph.D. in their respective scientific fields.
Who are Protalix BioTherapeutics' independent registered auditors?: Kesselman & Kesselman, Certified Public Accountant (Isr.), a member of PricewaterhouseCoopers International Limited, independent registered public accounting firm. Kesselman & Kesselman is located at Derech Menachem Begin 146, Tel Aviv 6107120, Israel, and can be reached at Tel: +972-3-795-4555 Fax: +972-3-795-4556.
When does Protalix BioTherapeutics' fiscal year end?: Protalix BioTherapeutics' fiscal year end is December 31.
How do I obtain information on Protalix BioTherapeutics?: Information regarding Protalix BioTherapeutics may be obtained through its news releases, presentations and other materials all of which may be accessed directly through this site. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, Proxy Statements and other filings with the U.S. Securities and Exchange Commission may be accessed directly through this site or through the U.S. Securities and Exchange Commission at www.sec.gov.
Who is Protalix BioTherapeutics' legal counsel?: Protalix BioTherapeutics’ legal team is Mayer Brown LLP; they may be reached at +1 (212) 506-2500.
Who can I contact for additional information regarding Protalix BioTherapeutics?: Investor and media inquiries can be directed to: ir@protalix.com or: Chuck Padala, LifeSci Advisors, LLC, Tel +1 (646) 627-8390, chuck@lifesciadvisors.com or Moran Meir Beres, LifeSci Advisors, LLC, Tel +972 (77) 693‑5513, moran@lifesciadvisors.com.
Who is Protalix BioTherapeutics' transfer agent and how does a registered shareholder contact the agent regarding account information?: Protalix BioTherapeutics’ transfer agent is American Stock Transfer & Trust Company, LLC. The transfer agent may be reached at +1 (800) 937-5449 or +1 (718) 921-8300. Please see www.astfinancial.com for additional information regarding the transfer agent.
What exchange does Protalix BioTherapeutics’ common stock trade on and what are its ticker symbol and pertinent identifier numbers?: Protalix BioTherapeutics' common stock trades on the NYSE American under the ticker symbol PLX and the CUSIP is 74365A309. Protalix BioTherapeutics’ U.S. ISIN is US74365A3095.
Who is Protalix BioTherapeutics’ Designated Market Maker on the NYSE American?: J. Streicher & Co., LLC
How many shares of common stock does Protalix BioTherapeutics' have outstanding?: As of May 15, 2023, Protalix BioTherapeutics had approximately 67,530,757 shares of its common stock, par value $0.001 per share, outstanding. This number gives effect to the 1-for-10 reverse stock split that went into effect on December 19, 2019.
Does Protalix BioTherapeutics pay a dividend?: No, Protalix BioTherapeutics does not pay a dividend.
When does Protalix BioTherapeutics release earnings?: Protalix BioTherapeutics currently discloses financial information in its Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q. Earnings releases are generally issued, and earnings calls are generally held, on the same day financial information is released.
When is Protalix BioTherapeutics' Annual Stockholders' Meeting?: The Protalix BioTherapeutics 2023 Annual Meeting of Stockholders is scheduled for June 28, 2023.
When was Protalix BioTherapeutics’ initial public offering?: Protalix BioTherapeutics became a U.S. public company through a reverse merger with Orthodontix Inc. on December 31, 2006. On October 25, 2007, Protalix BioTherapeutics issued and sold 10,000,000 shares of common stock in an underwritten public offering at a price of $5.00 per share.
When did Protalix BioTherapeutics become a public company?: Protalix BioTherapeutics became a U.S. public company through a reverse merger with Orthodontix Inc. on December 31, 2006.